Mehanna Stephanie, Mansour Najwa, Audi Hassib, Bodman-Smith Kikki, Mroueh Mohamad A, Taleb Robin I, Daher Costantine F, Khnayzer Rony S
Department of Natural Sciences, Lebanese American University Chouran Beirut 1102-2801 Lebanon
Faculty of Health and Medical Sciences, Department of Microbial and Cellular Sciences, University of Surrey UK.
RSC Adv. 2019 Jun 3;9(30):17254-17265. doi: 10.1039/c9ra02615k. eCollection 2019 May 29.
The use of ruthenium complexes as chemotherapeutic agents has been recently explored as one of the alternatives to conventional treatments. In the present study, two Ru(ii) polypyridyl complexes were synthesized and characterized: a strained [Ru(bipy)(BC)]Cl (complex 1) where [bipy = 2,2'-bipyridine and BC = bathocuproine] along with the unstrained control [Ru(bipy)(phen)]Cl (complex 2) where [phen = 1,10-phenanthroline]. The photophysical and photochemical analyses proved that unlike the photostable complex 2, complex 1 ejected both bipy and BC ligands at a ratio of 3 : 1 respectively. Results showed that the activity of complex 1 was significantly enhanced upon photoactivation. The response was however particularly significant in B16-F10 melanoma cells where phototoxicity index (PI = IC dark/IC light) was >900. When compared to cisplatin, the photoproducts were more potent against all tested cell lines, implying that the complex acquired significant chemotherapeutic potential upon irradiation. Cellular uptake of complex 1 and the free BC ligand were found to be significantly facilitated as evidenced by 400-600 fold increase in concentration of the compounds inside the cells relative to the extracellular culture medium. Complex 2 exhibited 35 times lower cellular concentration relative to complex 1. Flow cytometry and plasmid DNA gel electrophoresis measurements showed that complex 1 interacts with DNA inducing apoptosis in the dark and either late-apoptosis or necrosis upon irradiation. These findings corroborate the importance of lipophilic ligands such as BC to enhance uptake and subsequently improve the photochemotherapy potential of Ru(ii) polypyridyl complexes.
钌配合物作为化疗药物的应用最近已被探索为传统治疗的替代方法之一。在本研究中,合成并表征了两种Ru(ii)多吡啶配合物:一种是应变的[Ru(bipy)(BC)]Cl(配合物1),其中[bipy = 2,2'-联吡啶,BC = 邻菲罗啉铜],以及非应变对照[Ru(bipy)(phen)]Cl(配合物2),其中[phen = 1,10-菲咯啉]。光物理和光化学分析证明,与光稳定的配合物2不同,配合物1分别以3:1的比例释放出bipy和BC配体。结果表明,配合物1在光激活后活性显著增强。然而,在B16-F10黑色素瘤细胞中,这种反应尤为显著,其光毒性指数(PI = IC暗/IC光)>900。与顺铂相比,光产物对所有测试细胞系的活性更强,这意味着该配合物在辐照后获得了显著的化疗潜力。细胞对配合物1和游离BC配体的摄取被发现显著促进,细胞内化合物浓度相对于细胞外培养基增加了400-600倍,这证明了这一点。配合物2的细胞浓度相对于配合物1低35倍。流式细胞术和质粒DNA凝胶电泳测量表明,配合物1在黑暗中与DNA相互作用诱导细胞凋亡,辐照后诱导晚期凋亡或坏死。这些发现证实了亲脂性配体如BC对于增强摄取并随后提高Ru(ii)多吡啶配合物光化疗潜力的重要性。